Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia
Author:
Publisher
Elsevier BV
Subject
Hematology
Reference51 articles.
1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med.,2003
2. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival;Druker;N Engl J Med.,2006
3. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009
4. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response;Allan;Lancet,1995
5. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia;Arora;J Clin Oncol.,2009
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review;Frontiers in Oncology;2022-12-06
2. RAS-mediated oncogenic signaling pathways in human malignancies;Seminars in Cancer Biology;2019-02
3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia;Pharmacological Research;2017-06
4. Do polymorphisms inMDR1andCYP3A5genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?;Leukemia & Lymphoma;2017-04-03
5. Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes;Annals of Allergy, Asthma & Immunology;2016-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3